Gleevec's 25th Anniversary Highlights Transformative Impact on Cancer Treatment
Gleevec, a drug approved 25 years ago, has significantly transformed cancer treatment, particularly for chronic myeloid leukemia (CML). Initially developed by oncologist Brian Druker, Gleevec targets the genetic abnormality known as the Philadelphia chromosome, which causes uncontrolled cell growth in CML. The drug was part of a clinical trial in the late 1990s, where it showed unprecedented success in treating patients with this specific type of leukemia. The trials were notable for their rapid and positive results, leading to the drug's approval by the FDA in 2001. Gleevec was one of the first targeted cancer therapies, marking a shift from traditional chemotherapy to treatments that specifically target cancer cell growth mechanisms. The drug's development involved collaboration between public and private sectors, showcasing a successful model for medical advancements. 
